News

Filter

Current filters:

EPIRUS Biopharmaceuticals

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

12-06-2014

USA-based privately-held Epirus Biopharmaceuticals, focused on the development and commercialization…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBOW015EPIRUS BiopharmaceuticalsinfliximabRemicadeResearch

Epirus to acquire Zalicus, creating a publicly-traded biosimilars enterprise

16-04-2014

Boston-based privately-held Epirus Biopharmaceuticals, focused on the global development and commercialization…

BiosimilarsBiotechnologyEPIRUS BiopharmaceuticalsMergers & AcquisitionsZalicus

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

09-01-2014

India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) and EPIRUS Switzerland, a wholly-owned subsidiary…

Anti-Arthritics/RheumaticsBiosimilarsEPIRUS BiopharmaceuticalsGastro-intestinalsIndiainfliximabLicensingRanbaxy LaboratoriesRemicade

Phase III data support biosimilarity of BOW-015 to Remicade

29-08-2013

Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

Back to top